Table 1.

Characteristics of studies included in the meta-analysis.

Study	Study design	Blind	Patients numberRiociguat /placebo	Age (years)Riociguat /placebo	Dose	Duration(weeks)	Outcomes	Jadadscore
Ghofrani et al[15]	RCTs	double-blind	173/88	59 ± 14/59 ± 13	2.5 mg, t.i.d	16	6-MWD, Hemodynamics, PVRNT-proBNP, BDS, LPHSEQ-5D,Safety	5
Marra et al [16]	RCTs	double-blind	112/20	60 ± 13/--	1- 2.5 mg, t.i.d	52	6-MWD, NT-proBNP, safety	4
Simonneau et al [17]	RCTs	double-blind	155/82	59 ± 14/59 ± 12	2.5 mg, t.i.d	52	6-MWD, NT-proBNP, BDS, LPHSEQ-5D,Safety	4
Wang et al [18]	RCTs	double-blind	21/11	47 ± 10/52 ± 13	2.5 mg, t.i.d	16	6-MWD, PVR, NT-proBNP, BDSLPHS, EQ-5D,Safety	3